OBR Daily Commentary

forumImage

TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation By US FDA For The 1st-Line Treatment Of Patients With EGFR-Mutation Positive Non-Small Cell Lung Cancer

(AstraZeneca) Oct 9, 2017 - Designation based on positive Phase III FLAURA trial results; sixth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine.

Read Article arrow

H. Jack West, MD (Posted: October 09, 2017)

quotesThe data from FLAURA definitely support a first line approval, and the NCCN has just revised their guidelines in NSCLC to reflect that. The lung cancer community looks forward to a prompt approval of osimertinib in the first line setting. I have several patients in whom I am eager to prescribe osimertinib based on this indication. It can't happen soon enough.quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...